Frontiers Spring/Summer 2010
Forward Moves: New administrative leadership, two new divisions and a new division director
I have several exciting developments to share with you.
First, we are pleased to announce that Jeff Walker is returning to The Ohio State University to become the first executive director of our cancer program, effective June 1. Jeff will oversee all administrative, operational and fiscal functions for the OSUCCC – James, both clinical and research.
Jeff served as associate director for administration at Ohio State’s Comprehensive Cancer Center from 2001 to 2007. He then joined Roswell Park Cancer Institute in Buffalo, which, like our own James Cancer Hospital and Solove Research Institute, is a free-standing, PPS-exempt cancer hospital. As executive vice president, he oversaw the cancer center’s clinical and research operations.
Jeff’s experience and unique perspective will help move us toward our goal of becoming one of the nation’s top ten cancer programs.
In another exciting development, Ohio State’s Department of Internal Medicine has replaced the former Division of Hematology and Medical Oncology with an independent Division of Medical Oncology and an independent Division of Hematology. Having two distinct divisions will ensure the highest quality of patient care, education and research.
I am also pleased to announce that Miguel Villalona, MD, an outstanding leader from within our own ranks, was chosen to direct the new Division of Medical Oncology. He will also continue to direct our solid-tumor experimental therapeutics program.
A native of the Dominican Republic, Miguel is internationally recognized for his work in experimental therapeutics and lung cancer. He is an NCI-funded scholar and a member of the NCI investigational drug steering committee. He is an outstanding mentor, and as a member of the American Association for Cancer Research Council on Minorities in Cancer Research, and in other ways, he works to enhance minority scientist career development.
I hope you enjoy this issue of Frontiers and its stories about oncolytic virus therapy, how stimulus grants are furthering cancer research and the value of translational research. Read it as you travel to the American Society of Clinical Oncology meeting June 4-8 in Chicago.